Company intelligence / Profile preview

Connetics Australia

Rowville, Victoria, Australia

Ownership: Private
Employees: ~450
Development stage: Other

Overview

Connetics was a specialty pharmaceutical company dedicated to developing and commercializing high-value therapies for the dermatology market. The company distinguished itself through its proprietary VersaFoam technology, a versatile topical delivery platform designed to improve patient experience and efficacy in treating skin conditions. Its commercial portfolio featured leading products such as Olux and Luxiq for inflammatory scalp and skin disorders, as well as Evoclin for acne. In 2006, Connetics was acquired by Stiefel Laboratories for approximately $640 million, and its assets were later integrated into GSK following Stiefel's acquisition in 2009.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Solvay

Beyond the preview

Go deeper on Connetics Australia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Connetics Australia.

Explore the full profile